tbuckley/cabot-search huggingface dataset:
Abstract 17895: Rictor in Perivascular Adipose Tissue Reduces Aortic Contraction by Controlling Inflammation
Authors: Indranil Bhattacharya, Katja Drägert, Verena Albert, Rok Humar, Michael N Hall, Edouard J Battegay, Elvira Haas
Journal: Circulation (2013)

Introduction:  Mammalian target of rapamycin (mTOR) controls essential functions such as cellular growth and metabolism. The multiprotein mTOR kinase complex exists in two forms- mTOR complex 1 (mTORC1) and mTORC2. Rictor is an essential component of mTORC2 in adipose tissue and contributes to anti-inflammation in fibroblasts. The function of rictor in perivascular adipose tissue (PVAT), which forms a structural support around the arteries and has anti-contractile activity, is not known. Therefore, we hypothesized that rictor in PVAT may modulate vascular function through its anti-inflammatory property.   Method:  Adipose-specific rictor knockout mice (rictor ad-/- ) and littermate controls (rictor fl/fl ) were fed with standard chow diet till 20 weeks of age. Expression of rictor and pro-inflammatory molecules in PVAT was analyzed using qRT-PCR, bioplex assay and immunofluorescence. To assess the vascular function, experiments were performed with aortic rings with or without endothelium in the presence or absence of PVAT with phenylephrine (PE; 10 -9 -3x10 -6  M). Experiments were also performed in the presence of nitric oxide synthase inhibitor L-NAME or iNOS inhibitor 1400W. Infiltration of macrophages and leukocytes in stromal vascular fractions of PVAT were analysed with flow cytometry using specific antibodies F4/80 and CD45.2, respectively.   Results:  In rictor ad-/-  mice, expression of rictor was significantly reduced in PVAT but not in aorta. The contractions to PE were increased by 2-fold in rings with PVAT from rictor ad-/-  mice (43±6% vs. 20±3 %, n=10-13). The overall contractility was increased in rings after removal of PVAT and the contractile differences were not significant (70±9% vs. 81±10%, n=10-13). Contractions remained higher even after pre-treatment with L-NAME or after endothelium denudation in rings with PVAT lacking rictor. Expression of IL-6, TNFα, MIP1α and iNOS were significantly increased in PVAT from rictor ad-/-  mice but an increase in macrophage or leukocyte levels were not detected in PVAT (n=4-5). Inhibition of iNOS activity with 1400W inhibited the increased contractile response in rings with PVAT from rictor ad-/-  mice (n=7-11).   Conclusion:  mTORC2 in PVAT regulates normal vascular tone by controlling inflammation.
Abstract 18241: Impact of Annual Hospital Volume on In-Hospital Outcomes After Cardiac Transplantation
Authors: Kasra Moazzami, Elena Dolmatova, James M Maher, Pallavi Solanki, Marc Klapholz, Alfonso H Waller
Journal: Circulation (2016)

Introduction:  Limited evidence exists regarding the impact of annual hospital volume on outcomes in patients receiving heart transplant.   Hypothesis:  To quantify the impact of annual hospital volume on in-hospital mortality among patients receiving heart transplantation.   Methods:  Data from the National (Nationwide) Inpatient Sample (years 2008 to 2012) were analyzed to identify 11,104 patients receiving heart transplant. The study population was identified using validated international Classification of Diseases, Ninth Revision, Clinical Modification diagnosis (ICD-9-CM) and procedure codes. Annual hospital volume was calculated using unique hospital identifiers. Hospitals were divided into tertiles based on the volume of transplant cases admitted over the study period (low: 1-65, medium: 65-125, high> 125). Multivariate regression analysis was used to identify independent predictors of mortality in patients undergoing heart transplant.   Results:  Between the years of 2008 and 2012, a total of 519 (4.67%) in-hospital deaths occurred among recipients of heart transplantation. In-hospital mortality was highest (5.8%) in the low hospital volume and lowest (3.9%) in hospitals with high annual volume (p   Conclusion:  Hospital volume is an independent determinant for in-hospital mortality among patient receiving heart transplants.
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer
Authors: Wei Li, Takashi Tanikawa, Ilona Kryczek, Houjun Xia, Gaopeng Li, Ke Wu, Shuang Wei, Lili Zhao, Linda Vatan, Bo Wen, Pan Shu, Duxin Sun, Celina Kleer, Max Wicha, Michael Sabel, Kaixiong Tao, Guobin Wang, Weiping Zou
Journal: Cell Metabolism (2018)
Expression of the DNA-Binding Factor TOX Promotes the Encephalitogenic Potential of Microbe-Induced Autoreactive CD8+ T Cells
Authors: Nicolas Page, Bogna Klimek, Mathias De Roo, Karin Steinbach, Hadrien Soldati, Sylvain Lemeille, Ingrid Wagner, Mario Kreutzfeldt, Giovanni Di Liberto, Ilena Vincenti, Thomas Lingner, Gabriela Salinas, Wolfgang Brück, Mikael Simons, Rabih Murr, Jonathan Kaye, Dietmar Zehn, Daniel D. Pinschewer, Doron Merkler
Journal: Immunity (2018)
Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa
Authors: Amit Garg, Jessica Hundal, Andrew Strunk
Journal: JAMA Dermatology (2018)

Limited evidence supports a link between hidradenitis suppurativa (HS) and Crohn disease (CD), and this relationship has not been established in the United States.To evaluate the prevalence of CD among patients with HS in the United States and to determine the strength of association between the 2 conditions.Cross-sectional analysis of data from 51 340 patients with HS identified using electronic health records data in the Explorys multiple health system data analytics and research platform, which includes data from more than 50 million unique patients across all US census regions.Primary outcome was diagnosis of CD.Of the 18 455 660 total population considered, 51 340 had HS (35 000 women). Of these patients with HS, 29 010 (56.5%) were aged 18 to 44 years; 17 580 (34,2%), 45 to 64 years; and 4750 (9.3%), 65 years or older. Prevalence of CD among patients with HS was 2.0% (1025/51 340), compared with 0.6% (113 360/18 404 260) among those without HS (P < .001). Prevalence of CD was greatest among patients with HS who were white (2.3%), aged 45 to 64 years (2.4%), nonobese (2.8%), and tobacco smokers (2.3%). In univariable and multivariable analyses, patients with HS had 3.29 (95% CI, 3.09-3.50) and 3.05 (95% CI, 2.87-3.25) times the odds of having CD, respectively, compared with patients without HS. Crohn disease was associated with HS across all patient subgroups. The association was strongest for men (OR, 3.61; 95% CI, 3.24-4.03), patients aged 45 to 64 years (OR, 3.49; 95% CI, 3.16-3.85), nonobese patients (OR, 4.09; 95% CI, 3.69-4.54), and nonsmokers (OR, 3.44; 95% CI, 3.10-3.82).These data suggest that patients with HS are at risk for CD. Gastrointestinal symptoms or signs suggestive of CD warrant additional evaluation by a gastroenterologist.
Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment
Authors: Wouter B L van den Bossche, Anne Kleijn, Charlotte E Teunissen, Jane S A Voerman, Cristina Teodosio, David P Noske, Jacques J M van Dongen, Clemens M F Dirven, Martine L M Lamfers
Journal: Neuro-Oncology (2018)

Abstract Background Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material. Methods Human monocyte-derived macrophages were co-cultured with Delta24-RGD–infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD–treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD–treated GBM patient were compared with 5 control GBM patient samples by flow cytometry. Results Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD–infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD–treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD–treated patient showed significantly greater M1 characteristics than in control GBM tissue. Conclusion Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.
Advances in clinical chemistry. Volume 5.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression
Authors: Adrienne Tin, Girish Nadkarni, Anne M. Evans, Cheryl A. Winkler, Erwin Bottinger, Casey M. Rebholz, Mark J. Sarnak, Lesley A. Inker, Andrew S. Levey, Michael S. Lipkowitz, Lawrence J. Appel, Dan E. Arking, Josef Coresh, Morgan E. Grams
Journal: Journal of the American Society of Nephrology (2018)

Background Metabolite levels reflect physiologic homeostasis and may serve as biomarkers of disease progression. Identifying metabolites associated with APOL1 risk alleles—genetic variants associated with CKD risk commonly present in persons of African descent—may reveal novel markers of CKD progression relevant to other populations. Methods We evaluated associations between the number of APOL1 risk alleles and 760 serum metabolites identified via untargeted profiling in participants of the African American Study of Kidney Disease and Hypertension (AASK) ( n =588; Bonferroni significance threshold P &lt;6.5×10 −5 ) and replicated findings in 678 black participants with CKD in Bio Me , an electronic medical record–linked biobank. We tested the metabolite association with CKD progression in AASK, Bio Me , and the Modification of Diet in Renal Disease (MDRD) Study. Results One metabolite, 6-bromotryptophan, was significant in AASK ( P =4.7×10 −5 ) and replicated in Bio Me ( P =5.7×10 −3 ) participants, with lower levels associated with more APOL1 risk alleles. Lower levels of 6-bromotryptophan were associated with CKD progression in AASK and Bio Me participants and in white participants in the MDRD Study, independent of demographics and clinical characteristics, including baseline GFR (adjusted hazard ratio per two-fold higher 6-bromotryptophan level, AASK, 0.76; 95% confidence interval [95% CI], 0.64 to 0.91; Bio Me , 0.61; 95% CI, 0.43 to 0.85; MDRD, 0.52; 95% CI, 0.34 to 0.79). The interaction between the APOL1 risk alleles and 6-bromotryptophan was not significant. The identity of 6-bromotryptophan was confirmed in experiments comparing its molecular signature with that of authentic standards of other bromotryptophan isomers. Conclusions Serum 6-bromotryptophan is a consistent and novel risk factor for CKD progression.
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Authors: Rashmi Murthy, Virginia F Borges, Alison Conlin, Jorge Chaves, Marc Chamberlain, Todd Gray, Alex Vo, Erika Hamilton
Journal: The Lancet Oncology (2018)
Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness
Authors: Milica Grozdanovic, Kimberly G. Laffey, Hazem Abdelkarim, Ben Hitchinson, Anantha Harijith, Hyung-Geon Moon, Gye Young Park, Lee K. Rousslang, Joanne C. Masterson, Glenn T. Furuta, Nadya I. Tarasova, Vadim Gaponenko, Steven J. Ackerman
Journal: Journal of Allergy and Clinical Immunology (2018)
Early childhood developmental status in low- and middle-income countries: National, regional, and global prevalence estimates using predictive modeling: National, Regional, and Global Prevalence Estimates Using Predictive Modeling
Authors: Dana Charles McCoy, Evan D Peet, Majid Ezzati, Goodarz Danaei, Maureen M Black, Christopher R Sudfeld, Wafaie Fawzi, Günther Fink
Journal: PLoS Medicine (2016)
Non-coding RNAs in vascular disease – from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
Authors: Jan Fiedler, Andrew H Baker, Stefanie Dimmeler, Stephane Heymans, Manuel Mayr, Thomas Thum
Journal: Cardiovascular Research (2018)

Non-coding RNAs are increasingly recognized not only as regulators of various biological functions but also as targets for a new generation of RNA therapeutics and biomarkers. We hereby review recent insights relating to non-coding RNAs including microRNAs (e.g. miR-126, miR-146a), long non-coding RNAs (e.g. MIR503HG, GATA6-AS, SMILR), and circular RNAs (e.g. cZNF292) and their role in vascular diseases. This includes identification and therapeutic use of hypoxia-regulated non-coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth muscle cell signalling, age-related non-coding RNAs, and non-coding RNAs involved in the regulation of mitochondrial biology and metabolic control. Finally, we discuss non-coding RNA species with biomarker potential.This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.
Double blind placebo-controlled allergen-specific immunotherapy with the hypoallergenic folded variant of rBet v 1-FV in birch associated soy allergy
Authors: R. Treudler, A. Franke, A. Schmiedeknecht, B. Ballmer-Weber, M. Worm, T. Werfel, U. Jappe, T. Biedermann, J. Schmitt, R. Brehler, A. Kleinheinz, J. Kleine-Tebbe, H. Bruning, F. Ruëff, J. Ring, J. Saloga, K. Schakel, H. Merk, T. Holzhauser, S. Vieths, J. C. Simon
Journal: Allergy (2016)
Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression
Authors: Sunyoung Park, Soyun Cho, Minji Kim, Ji Ung Park, Eui Cheol Jeong, Euno Choi, Jeong Hwan Park, Cheol Lee, Mee Soo Chang
Journal: Journal of the American Academy of Dermatology (2018)
THE ENDOSCOPIC AND CLINICOPAHOLOGIC CHARACTERISTICS OF DE NOVO COLON CANCERS
Authors: J Park, JO Kim, SR Jeon, HG Kim, TH Lee, JS Lee
Journal: Endoscopy (2018)

Most colon cancers occurs via the adenoma-carcinoma sequence. Some colon cancers bypass this sequence and directly appears from normal tissues. We investigated the endoscopic and clinico-pathologic features of early colon cancers originating de novo.
Temporal Uptake Patterns of 18F-Fluorocholine Among Hyperfunctioning Parathyroid Glands
Authors: David Morland, Capucine Richard, François Godard, Sophie Deguelte, Brigitte Delemer
Journal: Clinical Nuclear Medicine (2018)

Optimal scan time of F-fluorocholine (FCH) PET/CT for localization of hyperfunctioning parathyroid glands is poorly documented. We report a small series of 9 histologically proven hyperfunctioning parathyroid gland with heterogeneous temporal uptake profile. Thirty-minute dynamic acquisition starting just after F-fluorocholine administration and delayed acquisition were recorded. Three different uptake patterns are seen (early washout, stable uptake, late increase) indicating the importance of an early (5-10 minutes) acquisition. A late acquisition (60 minutes) could be useful when the early acquisition is negative. No correlations were noted between uptake profile and histological or genetic results.
CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
Authors: Roberta Lugano, Kalyani Vemuri, Di Yu, Michael Bergqvist, Anja Smits, Magnus Essand, Staffan Johansson, Elisabetta Dejana, Anna Dimberg
Journal: Journal of Clinical Investigation (2018)

Tumor angiogenesis occurs through regulation of genes that orchestrate endothelial sprouting and vessel maturation, including deposition of a vessel-associated extracellular matrix. CD93 is a transmembrane receptor that is upregulated in tumor vessels in many cancers, including high-grade glioma. Here, we demonstrate that CD93 regulates β1 integrin signaling and organization of fibronectin fibrillogenesis during tumor vascularization. In endothelial cells and mouse retina, CD93 was found to be expressed in endothelial filopodia and to promote filopodia formation. The CD93 localization to endothelial filopodia was stabilized by interaction with multimerin-2 (MMRN2), which inhibited its proteolytic cleavage. The CD93-MMRN2 complex was required for activation of β1 integrin, phosphorylation of focal adhesion kinase (FAK), and fibronectin fibrillogenesis in endothelial cells. Consequently, tumor vessels in gliomas implanted orthotopically in CD93-deficient mice showed diminished activation of β1 integrin and lacked organization of fibronectin into fibrillar structures. These findings demonstrate a key role of CD93 in vascular maturation and organization of the extracellular matrix in tumors, identifying it as a potential target for therapy.
Abstract 12380: Preventing Tumor Formation Following iPS Cell-Derived Cardiomyocytes Transplantation Therapy by Carbohydrate Vaccine Therapy Targeting Undifferentiated iPS Cell-Specific Antigen
Authors: Takuji Kawamura, Shigeru Miyagawa, Satsuki Fukushima, Noriyuki Kashiyama, Ai Kawamura, Shohei Yoshida, Emiko Itou, Atsuhiro Saito, Akira Maeda, Hiroshi Eguchi, Koichi Toda, Shuji Miyagawa, Hiroomi Okuyama, Yoshiki Sawa
Journal: Circulation (2015)

Introduction: Cell transplantation therapy using induced pluripotent stem cell (iPSC)-derived cardiomyocyte (iPSC-CM) into damaged myocardium is a promising approach; however, the tumor formation from the remaining undifferentiated iPSCs in the graft is still a concern. We hypothesized that antigens specific to the undifferentiated iPSCs may provoke host immune response after transplantation, and that vaccine therapy targeting the antigen may minimize tumor formation following transplantation of iPSC-CMs. Methods and Results: Murine iPSCs or iPSC-CMs, were transplanted into syngeneic mice and then the antibodies against each cell in the serum were quantified as mean fluorescence intensity by flow cytometry. As a result, the anti-iPSC antibodies in the iPSC-immunized mice, but not the anti-iPSC-CM antibodies in the iPSC-CM-immunized mice, displayed significantly higher intensities (IgM, 1,400, IgG: 2,300) as compared to the normal (IgM: 180, IgG: 310). Of note, the antibodies against SSEA-1 were significantly increased in the serum of the iPSC-immunized mice (IgM: 219, IgG: 216), as compared to the normal (IgM: 59, IgG: 56), quantified by the enzyme-linked immunosorbent assay. It was thus indicated that SSEA-1 may be a target to induce undifferentiated iPSC-specific immune response. Then, we immunized mice with SSEA-1 conjugated CRM-197, which is reported to be an effective carrier protein to present carbohydrate antigens. In the serum of the SSEA-1-CRM-197-immunized mice, antibodies against the iPSCs (IgM: 1,600, IgG: 2,400) were significantly higher levels than those against the iPSC-CMs (IgM: 100, IgG: 200). In addition, CD4+ and CD19+ cells presented significantly higher proliferative responses against the transplanted iPSCs, resulting in depletion of more than 10^7 of the undifferentiated iPSCs in vivo. Finally, transplantation of the iPSC-CMs to the SSEA-1-CRM-197-immunized mice revealed the engraftment of the iPSC-CMs without the tumor formation (n=5). Conclusions: Carbohydrate vaccine targeting SSEA-1 induced the undifferentiated iPSC-specific immune response and enabled the iPSC-CMs to engraft without the tumor formation. This novel approach would be useful to ensure the safety of the iPSC transplantation therapy.
Gold nanoparticles in ophthalmology
Authors: Florence Masse, Mathieu Ouellette, Guillaume Lamoureux, Elodie Boisselier
Journal: Medicinal Research Reviews (2018)

Abstract Many research projects are underway to improve the diagnosis and therapy in ophthalmology. Indeed, visual acuity deficits affect 285 million people worldwide and different strategies are being developed to strengthen patient care. One of these strategies is the use of gold nanoparticles (GNP) for their multiple properties and their ability to be used as both diagnosis and therapy tools. This review exhaustively details research developing GNPs for use in ophthalmology. The toxicity of GNPs and their distribution in the eye are described through in vitro and in vivo studies. All publications addressing the pharmacokinetics of GNPs administered in the eye are extensively reviewed. In addition, their use as biosensors or for imaging with optical coherence tomography is illustrated. The future of GNPs for ophthalmic therapy is also discussed. GNPs can be used to deliver genes or drugs through different administration routes. Their antiangiogenic and anti‐inflammatory properties are of great interest for different ocular pathologies. Finally, GNPs can be used to improve stereotactic radiosurgery, brachytherapy, and photothermal therapy because of their many properties.
Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease
Authors: Elina Zuelgaray, Maxime Battistella, Camille Sallé de Chou, Marie-Dominique Vignon-Pennamen, Michel Rybojad, Antoine Petit, Florence Cordoliani, François Chasset, Claude Bachmeyer, Laurence Fardet, Bruno Fautrel, Patrice Cacoub, Dan Lipsker, Martine Bagot, Jean-David Bouaziz
Journal: Journal of the American Academy of Dermatology (2018)